Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“HER2+ updates keep rolling in…
Just ahead of ESMO2025, we’re seeing major momentum across the HER2+ spectrum – from early to metastatic disease.
- DESTINY-Breast05 – Adjuvant, high-risk HER2+ with residual disease
T-DXd outperformed T-DM1 head-to-head in invasive DFS. - DESTINY-Breast11 – Neoadjuvant, high-risk HER2+ eBC
Sequential T-DXd → THP beat AC-THP, reinforcing ADC-based strategies.
And outside of ESMO:
HER2CLIMB-05 just announced a positive press release – tucatinib + HP significantly improved PFS in the first-line maintenance setting for metastatic HER2+ disease.
Three wins. One message:
HER2-targeted innovation is moving earlier – and faster – than ever. This quite a time in breast oncology!!”
More post featuring Matthew Kurian on OncoDaily.